To hear about similar clinical trials, please enter your email below
Trial Title:
Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
NCT ID:
NCT05749289
Condition:
Neuroendocrine Tumor
Conditions: Official terms:
Neuroendocrine Tumors
Octreotide
Study type:
Interventional
Study phase:
Phase 2/Phase 3
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Al18F-octreotide
Description:
Al18F-octreotide I was injected into the patients before the PET/CT scans
Arm group label:
Al18F-octreotide PET/CT
Other name:
Al18F-NOTA-TATE
Summary:
This is an open-label whole-body PET/CT study for investigating the value of
Al18F-octreotide PET/CT in patients with Neuroendocrine Tumor
Detailed description:
Octreotide is an artificial replacement for the natural growth hormone inhibitor in
humans. It is a small peptide hormone consisting of 14 amino acids and is widely
distributed in neuroendocrine cells, with the highest density in the brain, peripheral
neurons, endocrine pancreas and gastrointestinal tract. Under pathological conditions,
some tumour cells show overexpression of growth inhibitory receptors, such as endocrine
tumours of the pancreas, pituitary adenomas, pheochromocytomas, paragangliomas, carcinoid
tumours, medullary thyroid carcinomas, small cell lung carcinomas and other
neuroendocrine tumours. Therefore, the sensitivity and specificity of octreotide imaging
is high.
This study will provide a visual, reproducible and non-invasive imaging method for the
diagnosis of neuroendocrine tumours through Al18F-octreotide PCT/CT imaging, providing an
intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and
treatment, contributing to the development of medicine and science in the field of
positron imaging.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patients with suspected or clearly diagnosed Neuroendocrine Tumor
- signed written consent.
- Willing and able to cooperate with all projects in this study.
Exclusion Criteria:
- pregnancy;
- breastfeeding;
- any medical condition that in the opinion of the investigator may significantly
interfere with study compliance.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Address:
City:
Beijing
Zip:
100021
Country:
China
Status:
Recruiting
Contact:
Last name:
Guozhu Hou, M.D.
Phone:
15611145656
Email:
15611145656@163.com
Start date:
December 20, 2022
Completion date:
December 20, 2025
Lead sponsor:
Agency:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Agency class:
Other
Source:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05749289
